Dihydroergocornine
| Names | |
|---|---|
| IUPAC name
(10αH)-12′-Hydroxy-2′,5′α-di(propan-2-yl)-9,10-dihydroergotaman-3′,6′,18-trione
| |
| Systematic IUPAC name
(6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-10b-Hydroxy-3,6-oxo-2,5-di(propan-2-yl)-octahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide | |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
| ECHA InfoCard | 100.042.705 |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C31H41N5O5 | |
| Molar mass | 563.687 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Dihydroergocornine is an ergot alkaloid. Alongside dihydroergocristine and dihydroergocryptine, it is one of the three components of ergoloid.[1]
Dihydroergocornine is less effective than ergotamine tartrate and dihydroergotamine in treating patients with typical migraine, but it is also less toxic.[2]
Dihydroergocornine can temporarily lower blood pressure and pulse rate intravenously, whereas oral administration has little effect.[3]
References
- ^ Steinhilber D, Schubert-Zsilavecz M, Roth HJ (2005). Medizinische Chemie (in German). Stuttgart, Germany: Deutscher Apotheker Verlag. p. 142. ISBN 3-7692-3483-9.
- ^ Bercel NA (April 1950). "TREATMENT OF MIGRAINE—Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives". Calif Med. 72 (4): 234–238. PMC 1520523. PMID 18731688.
- ^ TANDOWSKY, R. M. (1950-04-01). "The Clinical Effect of Dihydroergocornine Methanesulphonate (DHO-180) in Arterial Hypertension: A Preliminary Report". American Heart Association. 1 (4): 686–691. doi:10.1161/01.CIR.1.4.686.